AKYA vs. ATHA, PRLD, NAUT, HBIO, SEER, BNGO, PRE, RPID, AXDX, and OMIC
Should you be buying Akoya Biosciences stock or one of its competitors? The main competitors of Akoya Biosciences include Athira Pharma (ATHA), Prelude Therapeutics (PRLD), Nautilus Biotechnology (NAUT), Harvard Bioscience (HBIO), Seer (SEER), Bionano Genomics (BNGO), Prenetics Global (PRE), Rapid Micro Biosystems (RPID), Accelerate Diagnostics (AXDX), and Singular Genomics Systems (OMIC).
Athira Pharma (NASDAQ:ATHA) and Akoya Biosciences (NASDAQ:AKYA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, community ranking, media sentiment and profitability.
Athira Pharma has a beta of 2.83, indicating that its share price is 183% more volatile than the S&P 500. Comparatively, Akoya Biosciences has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500.
In the previous week, Athira Pharma and Athira Pharma both had 4 articles in the media. Akoya Biosciences' average media sentiment score of 1.55 beat Athira Pharma's score of 0.84 indicating that Athira Pharma is being referred to more favorably in the media.
Akoya Biosciences received 10 more outperform votes than Athira Pharma when rated by MarketBeat users. Likewise, 60.87% of users gave Akoya Biosciences an outperform vote while only 58.06% of users gave Athira Pharma an outperform vote.
57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 79.4% of Akoya Biosciences shares are held by institutional investors. 19.8% of Athira Pharma shares are held by company insiders. Comparatively, 7.3% of Akoya Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Athira Pharma has a net margin of 0.00% compared to Athira Pharma's net margin of -72.68%. Akoya Biosciences' return on equity of -80.59% beat Athira Pharma's return on equity.
Athira Pharma presently has a consensus target price of $19.00, indicating a potential upside of 625.19%. Akoya Biosciences has a consensus target price of $7.79, indicating a potential upside of 262.13%. Given Akoya Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Athira Pharma is more favorable than Akoya Biosciences.
Akoya Biosciences has higher revenue and earnings than Athira Pharma. Akoya Biosciences is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
Athira Pharma and Akoya Biosciences tied by winning 8 of the 16 factors compared between the two stocks.
Get Akoya Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKYA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AKYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Akoya Biosciences Competitors List
Related Companies and Tools
